Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for rheumatoid arthritis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoidarthritis To develop and evaluate an adjusted score for the multi-biomarker disease activity (MBDA) test to account for the effects of age, sex and adiposity in patients with RA.Two models were developed to adjust MBDA score for age, sex and adiposity, using either serum leptin concentration or BMI as proxies for adiposity. Two cohorts were studied. A cohort of 325 781 RA
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoidarthritis: a multidatabase cohort study To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoidarthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors (TNFi) or abatacept.Using claims data from US Medicare from 2010 to 2015, and IMS and MarketScan from 2011 to 2015, we identified adults with RA who initiated TCZ or TNFi
Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in RheumatoidArthritis: The IMAGINE-RA Randomized Clinical Trial. Whether using magnetic resonance imaging (MRI) to guide treatment in patients with rheumatoidarthritis (RA) improves disease activity and slows joint damage progression is unknown.To determine whether an MRI-guided treat-to-target strategy vs a conventional clinical treat-to-target strategy
Risk of serious infections in patients with rheumatoidarthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden To estimate (1) crude and age-and gender-adjusted incidence rates (IRs) of serious infections (SI) and (2) relative risks (RR) of SI in patients with rheumatoidarthritis (RA) initiating treatment with abatacept, rituximab or tocilizumab in routine care.This is an observational cohort study conducted in parallel in Denmark and Sweden including
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoidarthritis Safety and efficacy of mAbs blocking the IL-6 receptor have been established in RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab administered as single or multiple doses in patients with RA within the same study.In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks' double-blind sarilumab 150 or 200 mg every 2 weeks s.c
Effectiveness of a Referral Program for rheumatoidarthritis and axial spondyloarthritis Diagnosis at Primary Care Centers in Portugal - SIARA STUDY. Early diagnosis and treatment of RheumatoidArthritis (RA) and axial Spondylarthritis (axial SpA) can limit the impact of disease outcomes. This study evaluated the effectiveness of a referral program on the identification of patients with RA and axial SpA.This was an observational, prospective, randomized (by clusters) study conducted in Portugal (...) or axial SpA cases confirmed by the rheumatologist of the reference hospital.RA-Substudy: A total of 340 patients were recruited (144 in the RSA-exposed group; 196 in the control). RA diagnosis confirmation was 7.3% (95%CI, 2.1-12.5%) in RSA group versus 2.7% (95%CI, 0.0-5.7%) in control group RSA effect was positive but moderate (4.6%) and not statistically significant (95% CI, 0.0%-11.8%; p=0.222, adjusted for clustering effect). Rate of confirmed arthritis of any type was 16.9% (n=14/83) in the RSA
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoidarthritis and inadequate response to TNF inhibitors: prospective cohort study. To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors (rituximab, abatacept, and tocilizumab) in the treatment of rheumatoid arthritis.Population based prospective study.53 university and 54 non-university clinical centres in France.3162 adults (>18 years) with rheumatoidarthritis (...) according to 1987 American College of Rheumatology criteria, enrolled in one of the three French Society of Rheumatology registries; who had no severe cardiovascular disease, active or severe infections, or severe immunodeficiency, with follow-up of at least 24 months.Initiation of intravenous rituximab, abatacept, or tocilizumab for rheumatoid arthritis.The primary outcome was drug retention without failure at 24 months. Failure was defined as all cause death; discontinuation of rituximab, abatacept
Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in RheumatoidArthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial. Etanercept, a tumor necrosis factor inhibitor, is used to treat rheumatoidarthritis (RA) and psoriatic arthritis (PsA), and is administered via subcutaneous injection. Injection site pain (ISP) associated with subcutaneous administration may affect compliance or hinder initiation of prescribed medications. To improve
Immunogenicity of Sarilumab Monotherapy in Patients with RheumatoidArthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoidarthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs.Adults with RA (n = 132) were randomized to receive
Relative Impact of Pain and Fatigue on Work Productivity in Patients with RheumatoidArthritis from the RA-BEAM Baricitinib Trial. To explore the relationship of pain and fatigue with daily activity and work productivity in rheumatoidarthritis (RA) patients from the baricitinib clinical trial, RA-BEAM.In RA-BEAM, a double-blind phase 3 study, patients were randomized 3:3:2 to placebo (n = 488), baricitinib 4 mg once daily (n = 487), or adalimumab 40 mg biweekly (n = 330) with background
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe RheumatoidArthritis: A Phase IIb, Open-Label Extension Study. Peficitinib is a novel orally bioavailable, once-daily Janus kinase (JAK) inhibitor approved in Japan for the treatment of rheumatoidarthritis (RA). This 2-year extension study of two global phase IIb trials investigated the long-term safety and effectiveness of peficitinib.All eligible patients with moderate-to-severe RA including patients in the placebo group
Baricitinib (Olumiant) - moderate to severe rheumatoidarthritis (RA) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after
Effects of B-cell directed therapy on the preclinical stage of rheumatoidarthritis: the PRAIRI study We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoidarthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development.Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double (...) -blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo.Eighty-one individuals received treatment and were followed up for a mean of 29.0 (0-54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk of developing arthritis in the placebo-treated group was 40%, which was decreased by 55% (HR 0.45, 95% CI 0.154 to 1.322) in the rituximab-treated group at 12 months. Rituximab treatment caused a delay in arthritis development of 12
RheumatoidArthritis. Rheumatoidarthritis (RA) is a common systemic inflammatory autoimmune disease characterized by painful, swollen joints that can severely impair physical function and quality of life. The presenting symptoms of musculoskeletal pain, swelling, and stiffness are common in clinical practice, so familiarity with diagnosing and managing RA is crucial. Patients with RA are at greater risk for serious infection, respiratory disease, osteoporosis, cardiovascular disease, cancer
RheumatoidarthritisRheumatoidarthritis - NICE CKS Share Rheumatoidarthritis: Summary Rheumatoidarthritis (RA) is a chronic systemic inflammatory disease. RA typically presents as inflammatory arthritis affecting the small joints of the hands and the feet (usually both sides equally and symmetrically) although any synovial joint can be involved. As RA progresses, any system of the body may be affected, leading to an increased risk of premature death. RA is associated with a number (...) and Care Excellence (NICE) guidelines Rheumatoidarthritis in adults: management [ ], Rheumatoidarthritis: national clinical guideline for management and treatment in adults [ ], the American College of Rheumatology (ACR) Guideline for the treatment of rheumatoidarthritis [ ], the European League Against Rheumatism (EULAR) 2016 update of the EULAR recommendations for the management of early arthritis [ ], the British Medical Journal (BMJ) best practice guide RheumatoidArthritis [ ], expert opinion